Regeneron Pharmaceuticals Inc (REGN) - News Archive

As the biopharmaceutical industry continues to evolve, Regeneron Pharmaceuticals is at the forefront of innovation, evidenced by their robust pipeline advancements spanning multiple modalities and conditions. At the upc...

Dupixent (dupilumab) Gains Landmark EU Approval for Treating Eosinophilic Oesophagitis in Young Children In a significant advancement for paediatric healthcare, the European Union has granted approval for dupilumab, com...

Dupixent s Expanding Horizons: A Game-Changer in Combating Respiratory Diseases and Allergic Conditions Beijing, China - The healthcare landscape continues to be redefined as Dupixent (dupilumab) sets unprecedented mile...

CSIMarket.com Dupixent (dupilumab), a biologic therapy developed by Regeneron Pharmaceuticals Inc. has received a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) for its use in tre...

In a remarkable advancement for the treatment of chronic respiratory conditions and advanced cancers, the U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as the first and only treatment option...

Breaking New Ground: Dupixent (Dupilumab) Emerges as a Pioneering Biologic Therapy for Chronic Spontaneous Urticaria and Chronic Respiratory DiseasesIn the evolving landscape of biologic therapies, Dupixent (dupilumab)...

Libtayo (Cemiplimab): A Beacon of Hope in Advanced Non-Small Cell Lung Cancer Five-Year Survival Data Illuminate the Path ForwardIn the ever-evolving landscape of oncology, where breakthroughs are pivotal, Libtayo (cemi...

Advances in Dupilumab, Itepekimab, and Linvoseltamab: Leading the Way in Respiratory and Immunological Diseases The pharmaceutical industry continuously explores innovative treatments for chronic and debilitating diseas...

Breaking New Grounds in Therapy: Dupilumab s Unprecedented Approval for COPD and Linvoseltamab s Promising Results in Multiple Myeloma Recent advancements in targeted therapies have solidified their role in the treatmen...

In recent groundbreaking news, the European Medicines Agency s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of odronextamab for the treatment of relapsed/refractory follicular lymph...

In recent publications, The New England Journal of Medicine and the American Society of Clinical Oncology (ASCO) have reported positive findings regarding the use of Dupixent (dupilumab) and REGN7075 in treating various...

Multiple myeloma is a challenging hematologic malignancy characterized by the overproduction of abnormal plasma cells. Despite advancements in treatment, patients with heavily pre-treated multiple myeloma often face lim...

Dupixent (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demo...

In a development that has caught the attention of investors and stakeholders alike, Pomerantz LLP has launched an investigation into potential claims on behalf of investors of Regeneron Pharmaceuticals, Inc. (NASDAQ: RE...

Innovative Therapeutic Approaches Show Promising Results in Oncology, Genetic Deafness, and Retinal Diseases The landscape of therapeutic interventions is witnessing groundbreaking advancements in the treatment of chall...

Dupixent and EYLEA: Promising Advances in the Treatment of Chronic Obstructive Pulmonary Disease and Eye Disorders CSIMarket.com is pleased to present the latest research updates on two groundbreaking pharmaceuticals: D...

In the burgeoning landscape of pharmaceutical science, novel treatments continue to demonstrate potential in managing and treating a variety of conditions, from chronic respiratory diseases to retinal anomalies, and eve...

The field of pharmaceutical sciences has witnessed significant breakthroughs recently, with several studies showcasing the impressive potential of gene therapy in treating various genetic conditions. In this article, we...

EYLEA, also known as aflibercept, has continued to demonstrate its consistency and durability in maintaining efficacy and safety among this patient population. This data and additional subgroup analyses formed a key par...

In a recent collaborative initiative, Regeneron and Mammoth Biosciences have joined forces to explore the possibilities of next-generation CRISPR-based gene editing for the treatment of various diseases. The partnership...